ArticleMedicine2026
Utilizing drugs, food, and natural product libraries: A computational approach to targeting PGAM1 in clinical cancer therapy.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphoglycerate mutase 1 (PGAM1) is an important glycolytic enzyme that plays a significant role in cancer metabolism. It catalyzes the conversion of 3-phosphoglycerate (3-PG) to 2-phosphoglycerate (2-PG), facilitating energy release during glycolysis. PGAM1 is often upregulated in various cancers, including breast, lung, and prostate cancers, contributing to tumor growth and progression by coordinating glycolysis and anabolic processes which makes it an appealing target for drug development. In this study, we screened drugs, food, and natural compound libraries against PGAM1 by using structure based virtual screening approach. A total of 100 compounds from each library were screened and then docked to find the best plausible modes of the hits. Based on the binding affinities, 5 compounds from each library were selected for molecular interactions analysis. After analyzing the interactions, the top compound from each library was subjected to 200 ns simulation to check the effect of hits on the protein. The simulation results revealed that the hits made stable interactions with the protein during simulation and no confirmational changes were observed in the structure of protein. All these findings suggest that the selected compounds can serve as lead compounds in inhibiting the biological activity of PGAM1, but it requires further experimental investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.